Background Inhibition of p38 alpha mitogen activated protein kinase (p38α) has shown
great promise as a treatment for Alzheimer's disease (AD) in preclinical tests. However …

There are an estimated 6 million people with Down syndrome (DS) worldwide. In developed
countries, the vast majority of these individuals will develop Alzheimer's disease …

Background: Alzheimer's disease (AD) research has relied on mouse models
overexpressing human mutant A βPP; however, newer generation knock-in models allow for …

Genetically modified mice are engineered as models for human diseases. These mouse
models include inbred strains, mutants, gene knockouts, gene knockins, and …

Increasing efforts have been made in the last decades to increase the face validity of
Alzheimer's disease (AD) mouse models. Main advancements have consisted in generating …

Alzheimer's disease (AD) is a complex neurodegenerative disease whose risk is influenced
by genetic and environmental factors. Although a number of pathological hallmarks have …

Region-specific synapse loss is an early pathological hallmark in Alzheimer's disease (AD).
Emerging data in mice and humans highlight microglia, the brain-resident macrophages, as …

Alzheimer's disease (AD) progresses with memory loss and neuropsychiatric symptoms
associated with cell specific vulnerability in memory-and emotion-related neural circuits …

Background: Emerging evidence has revealed that dysregulation of the hormone ghrelin
and its receptor, growth hormone secretagogue receptor (GHSR), contributes to the …

Aging can be associated with the accumulation of hypobranched glycogen molecules
(polyglucosan bodies, PGBs), particularly in astrocytes of the hippocampus. While PGBs …